FILGRASTIM for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 14 adverse event reports in the FDA FAERS database where FILGRASTIM was used for Transitional cell carcinoma.
Most Reported Side Effects for FILGRASTIM
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 1,930 | 13.0% | 387 | 578 |
| Febrile neutropenia | 1,570 | 10.5% | 336 | 848 |
| Neutropenia | 1,431 | 9.6% | 277 | 419 |
| Death | 1,213 | 8.2% | 1,209 | 230 |
| Pyrexia | 1,085 | 7.3% | 200 | 618 |
| Diarrhoea | 739 | 5.0% | 196 | 326 |
| Nausea | 718 | 4.8% | 152 | 335 |
| Bone pain | 706 | 4.7% | 53 | 334 |
| Thrombocytopenia | 697 | 4.7% | 199 | 269 |
| Anaemia | 626 | 4.2% | 176 | 290 |
| Drug ineffective | 614 | 4.1% | 174 | 231 |
| Fatigue | 581 | 3.9% | 118 | 264 |
| Pneumonia | 562 | 3.8% | 319 | 252 |
| Sepsis | 543 | 3.7% | 375 | 234 |
| Vomiting | 520 | 3.5% | 141 | 243 |
Other Indications for FILGRASTIM
Product used for unknown indication (4,036)
Neutropenia (2,010)
Prophylaxis (1,197)
Haematopoietic stem cell mobilisation (988)
Acute lymphocytic leukaemia (619)
Febrile neutropenia (380)
Acute myeloid leukaemia (344)
Off label use (253)
Autologous haematopoietic stem cell transplant (193)
B-cell lymphoma (191)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)